The changing role of ER in endocrine resistance

• Published in: Breast (Edinburgh) Vol. 24; no. 2; pp. S60 - S66
• Main Authors: Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V, Osborne, C. Kent, Schiff, Rachel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.11.2015
• Subjects: Antineoplastic Agents, Hormonal - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Co-regulators; Crosstalk; Drug Resistance, Neoplasm; Endocrine resistance; ER genomic aberrations; Estrogen receptor; Female; Hematology, Oncology and Palliative Medicine; Humans; Protein-Tyrosine Kinases - metabolism; Receptor Cross-Talk; Receptors, Estrogen - antagonists & inhibitors; Receptors, Estrogen - genetics; Receptors, Estrogen - metabolism; Signal Transduction; Co-regulators; Estrogen receptor; Endocrine resistance; Breast cancer; ER genomic aberrations; Crosstalk
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2015.07.015

Abstract Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although endocrine therapy targeting ER is highly effective, intrinsic or acquired resistance is common, significantly jeopardizing treatment outcomes and minimizing overall survival. Even in the presence of endocrine resistance, a continued role of ER signaling is suggested by several lines of clinical and preclinical evidence. Indeed, inhibition or down-regulation of ER reduces tumor growth in preclinical models of acquired endocrine resistance, and many patients with recurrent ER+ breast tumors progressing on one type of ER-targeted treatment still benefit from sequential endocrine treatments that target ER by a different mechanism. New insights into the nature and biology of ER have revealed several mechanisms sustaining altered ER signaling in endocrine-resistant tumors, including deregulated growth factor receptor signaling that results in ligand-independent ER activation, unbalanced ER co-regulator activity, and genomic alterations involving the ER gene ESR1 . Therefore, biopsies of recurrent lesions are needed to assess the changes in epi/genomics and signaling landscape of ER and associated pathways in order to tailor therapies to effectively overcome endocrine resistance. In addition, more completely abolishing the levels and activity of ER and its co-activators, in combination with selected signal transduction inhibitors or agents blocking the upstream or downstream targets of the ER pathway, may provide a better therapeutic strategy in combating endocrine resistance.